Department of Otolaryngology-Head and Neck Surgery, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Center for Molecular Medicine, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Int J Pediatr Otorhinolaryngol. 2021 Jun;145:110715. doi: 10.1016/j.ijporl.2021.110715. Epub 2021 Apr 20.
Biallelic mutations in LOXHD1 have been identified as the cause of DFNB77 (deafness, autosomal recessive 77). It is a new progressive, severe-to-profound, and late-onset nonsyndromic sensorineural hearing loss (NSHL), and is highly heterogeneous genetically and phenotypically. This study aimed to provide an additional three cases of DFNB77.
We presented three unrelated children diagnosed with prelingual mild-to-severe NSHL, and their audiograms showed mild hearing loss at 250 Hz before downsloping to a moderate-to-severe degree. Trio whole-exome sequencing (WES) was conducted to identify the pathogenic variants. Additionally, we reviewed the literature to further analyze the relationships between the genotype and audiology phenotype of LOXHD1.
Six novel possible pathogenic LOXHD1 variants were identified, including three missense, one nonsense, and two splicing variants. The literature review showed that 68.5% of patients with DFNB77 onset before five years old; Most variants (62%) were associated with a down-sloping audiogram of mild-to-moderate hearing loss at low frequencies (200Hz, 500Hz), particularly variants in the protein domain of PLAT 9. We found that compared with homozygous LOXHD1 variants, individuals with heterozygous compound variants had a significantly milder phenotype, especially individuals carrying one missense and one splicing or bi-allelic missense variants (P < 0.05). Audiometric analysis at different ages showed that the hearing loss degree was aggravated at all frequencies by increasing age.
We report three children with prelingual NSHL carrying six novel LOXHD1 variants. Furthermore, our work indicates that DFNB77 may be milder than previously reported and recommends considering the genotype combination and mutation location of LOXHD1 and race-specificity in DFNB77 molecular diagnoses and management.
LOXHD1 的双等位基因突变已被确定为 DFNB77(耳聋,常染色体隐性 77)的病因。这是一种新的进行性、严重至重度、迟发性非综合征性感觉神经性听力损失(NSHL),在遗传和表型上高度异质。本研究旨在提供另外三个 DFNB77 病例。
我们介绍了三个不相关的儿童,他们被诊断为语前轻度至重度 NSHL,他们的听力图显示在低频(250 Hz)轻度听力损失,然后逐渐下降至中度至重度。进行了三体外显子组测序(WES)以鉴定致病变体。此外,我们回顾了文献,以进一步分析 LOXHD1 的基因型和听力学表型之间的关系。
鉴定出六个可能的新致病性 LOXHD1 变体,包括三个错义、一个无义、两个剪接变体。文献回顾显示,68.5%的 DFNB77 患者发病年龄在五岁以下;大多数变体(62%)与低频(200 Hz、500 Hz)轻度至中度听力损失的下倾听力图相关,特别是 PLAT 9 蛋白结构域的变体。我们发现,与纯合 LOXHD1 变体相比,杂合复合变体个体的表型明显更轻,特别是携带一个错义变体和一个剪接或双等位错义变体的个体(P < 0.05)。不同年龄的听力分析表明,随着年龄的增长,所有频率的听力损失程度都加重。
我们报告了三个携带六个新 LOXHD1 变体的语前 NSHL 儿童。此外,我们的工作表明,DFNB77 可能比之前报道的更轻,建议在 DFNB77 分子诊断和管理中考虑 LOXHD1 的基因型组合和突变位置以及种族特异性。